Janchor Partners
Janchor Partners Ltd. is a hedge fund management firm established in 2009 that focuses on long-term industrialist investments. The firm partners with companies that exhibit superior business models and favorable growth prospects, particularly within Asian markets. Janchor Partners aims to enhance long-term corporate value by acting as a thoughtful partner to its investee companies, fostering deep relationships built on insight and trust. This collaborative approach is designed to create sustainable value and positive impacts over time. The firm's investment strategy is supported by a network of high-quality global institutional investors, including family offices, university endowments, foundations, and pension funds, who commit their capital for extended periods. Through this model, Janchor Partners seeks to achieve holistic outcomes that benefit all stakeholders involved.
10 past transactions
Eden Brew
Series A in 2023
Eden Brew is a food and beverage company focused on producing animal-free and precision-fermented milk and dairy products. The company aims to provide an environmentally sustainable alternative to traditional cow's milk, offering dairy products that are vegan-friendly and lactose-free. Using precision fermentation technology, Eden Brew creates milk that contains nature-identical proteins and nutrients, allowing consumers to enjoy the taste and nutritional benefits of dairy without the environmental impact associated with conventional dairy farming.
FPL Technologies
Series C in 2021
FPL Technologies Pvt. Ltd., founded in 2019 and headquartered in Mumbai, India, focuses on providing innovative financial solutions for a digitally savvy younger population. The company has developed a proprietary technology platform that aims to enhance the credit card experience, capitalizing on the growing demand for consumption credit in India. With the recent surge in digital payment adoption, FPL recognizes the need for a more user-friendly approach to credit management. Their flagship product, the One Score app, launched to help users check and understand their credit scores, offers a secure and straightforward way to manage credit behavior. By integrating an intuitive mobile application with their credit card services, FPL Technologies seeks to meet the evolving needs of millennials and improve their overall financial literacy and credit experience.
MediTrust Health
Series C in 2021
MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.
Abbisko Therapeutics
Series D in 2021
Abbisko Therapeutics is a clinical-stage biopharmaceutical company focused on discovery and development of differentiated small-molecule oncology therapies. Based in Shanghai, China, and founded in 2016, the company emphasizes immuno-oncology and aims to advance cancer treatments through in-house research and development, with a focus on therapies for hepatocellular carcinoma and solid tumors.
InventisBio
Series D in 2020
InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company has developed a range of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Among its notable products is D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in creating targeted immuno-oncology therapies that can be used in combination with existing treatments, such as PD-1 antibodies, to address various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with extensive experience in drug discovery at major pharmaceutical companies, InventisBio aims to provide effective therapies for significant health challenges.
Everest Medicines
Series C in 2020
Everest Medicines is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for critical unmet medical needs, initially focusing on Asia Pacific markets.
Remegen
Venture Round in 2020
Remegen is a Chinese biopharmaceutical company focused on developing novel biologics, primarily monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), to address unmet medical needs in life-threatening conditions. Headquartered in Yantai with labs/offices in Beijing and California, Remegen's portfolio includes Telitacicept for systemic lupus erythematosus and Disitamab Vedotin for various cancers.
Rongchang Pharmaceutical
Series A in 2020
Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.
Alphamab Oncology
Series A in 2018
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the research, development, manufacture, and commercialization of innovative oncology biologics. Its pipeline includes bispecific monoclonal antibodies targeting immune checkpoints like PD-L1/CTLA-4 (KN046), next-generation anti-HER2 antibodies (KN026), CTLA-4 immunosuppressant fusion proteins (KN019), and injectable PD-L1 inhibitors for various cancer types (KN035). Founded in 2008, the company is headquartered in Suzhou, China.
FirstMeridian
Private Equity Round in 2018
FirstMeridian is a human resources investment platform that leverages technology and innovation to provide comprehensive HR services. The company specializes in general and professional staffing, permanent recruitment, managed services, and HR technology and automation. By focusing on these areas, FirstMeridian aims to enhance economic opportunities for the workforce, ultimately transforming lives through improved employment solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.